BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN), today announced data highlighting preclinical findings on two of its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data are being presented at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) International Conference on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.
